CELL-TYPE SPECIFIC REGULATION OF IL-1R SIGNALING BY R835, A DUAL IRAK1/4 INHIBITOR

被引：0
|
作者：
Braselmann, S. [1 ]
Tai, E. [1 ]
Frances, R. [1 ]
Young, C. [1 ]
Markovtsov, V. [1 ]
Masuda, E. [1 ]
Taylor, V. [1 ]
机构：
[1] Rigel Pharmaceut, San Francisco, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.3852
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0058
引用
收藏
页码：1327 / 1327
页数：1
相关论文
共 50 条
  • [1] PRECLINICAL EFFICACY OF R835, A NOVEL IRAK1/4 DUAL INHIBITOR, IN RODENT MODELS OF JOINT INFLAMMATION
    Lamagna, C.
    Chan, M.
    Tai, E.
    Siu, S.
    Frances, R.
    Yi, S.
    Young, C.
    Markovtsov, V.
    Chen, Y.
    Chou, L.
    Park, G.
    Masuda, E.
    Taylor, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 86 - 86
  • [2] FIRST-INHUMAN STUDY OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IRAK1/4 INHIBITOR R835 IN HEALTHY SUBJECTS
    Yan, L.
    Tong, S.
    Absalom, A.
    Daas, I. D.
    Park, G.
    Taylor, V.
    Chow, D.
    Lee, M.
    Zheng, H.
    Chow, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 332 - 332
  • [3] R835, A NOVEL IRAK1/4 DUAL INHIBITOR IN CLINICAL DEVELOPMENT, BLOCKS TOLL-LIKE RECEPTOR 4 (TLR4) SIGNALING IN HUMAN AND MOUSE
    Lamagna, C.
    Gundel, C.
    Chan, M.
    Young, C.
    Braselmann, S.
    Frances, R.
    Yi, S.
    Chen, Y.
    Park, G.
    Chou, L.
    Masuda, E.
    Taylor, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 575 - 575
  • [4] TARGETING IRAK1 AND 4 SIGNALING WITH R835, A NOVEL ORAL SMALL MOLECULE INHIBITOR: A POTENTIAL NEW TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS
    Lamagna, C.
    Chan, M.
    Bagos, A.
    Tai, E.
    Young, C.
    Chen, Y.
    Chou, L.
    Park, G.
    Masuda, E.
    Taylor, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 30 - 30
  • [5] IRAK4 in TLR/IL-1R signaling: Possible clinical applications
    Li, Xiaoxia
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (03) : 614 - 618
  • [6] A noncanonical IRAK4-IRAK1 pathway counters DNA damage-induced apoptosis independently of TLR/IL-1R signaling
    Li, Yuanyuan
    Shah, Richa B.
    Sarti, Samanta
    Belcher, Alicia L.
    Lee, Brian J.
    Gorbatenko, Andrej
    Nemati, Francesca
    Yu, Honglin
    Stanley, Zoe
    Rahman, Mahbuba
    Shao, Zhengping
    Silva, Jose M.
    Zha, Shan
    Sidi, Samuel
    SCIENCE SIGNALING, 2023, 16 (816)
  • [7] Tumor cell-specific IL1/IL-1R signaling promotes KRAS mutant lung tumorigenesis
    Krishna, Avantika
    Clowers, Michael J.
    Yuan, Bo
    Mutala, Milind
    Sancristobal, Maria Jose Arredondo
    Colunga, Jocelynn
    De Maleki, Ryan
    Phan, Linda
    Kadara, Humam
    Moghaddam, Seyed Javad
    CANCER RESEARCH, 2023, 83 (07)
  • [8] Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling
    Lin, Su-Chang
    Lo, Yu-Chih
    Wu, Hao
    NATURE, 2010, 465 (7300) : 885 - U2
  • [9] IL-1/IL-1R Signaling in Head and Neck Cancer
    Niklander, Sven E.
    Murdoch, Craig
    Hunter, Keith D.
    FRONTIERS IN ORAL HEALTH, 2021, 2
  • [10] Human cytokine gene nucleotide sequence alignments: interleukin 1 receptor (IL-1R) type II, IL-1R accessory protein, IL-1R antagonist, IL-2 and IL-3
    Laundy, GJ
    Bidwell, JL
    EUROPEAN JOURNAL OF IMMUNOGENETICS, 2002, 29 (06): : 541 - +
12345